Integrated Chinese and Western medicine prolong survival in colorectal cancer with liver metastasis: A retrospective cohort study

doi:10.5306/wjco.v17.i5.118265

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 5

This Article

(26)

(27)

(0)

(43)

(1)

(474)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Clin Oncol. May 24, 2026; 17(5): 118265
Published online May 24, 2026. doi: 10.5306/wjco.v17.i5.118265

Table 3 Subgroup analysis forest plot

Subgroup	mOS/month (95%CI)		χ²	HR (95%CI)	P value
Subgroup	Cohort A	Cohort B	χ²	HR (95%CI)	P value
Age
< 65 years	39.87 (33-48.5)	28.62 (25.4-31.8)	15.16	0.59 (0.45-0.77)	< 0.01^b
≥ 65 years	31 (28-41)	27.13 (22.3-32.47)	4.58	0.70 (0.50-0.97)	0.03^a
Sex
Male	36 (31-45.27)	30.57 (26.4-34.53)	6.25	0.70 (0.53-0.92)	0.01^a
Female	35.57 (30.8-44)	25.37 (22.53-28.4)	12.55	0.70 (0.51-0.97)	< 0.01^b
Side
Left	36.53 (32.47-44)	32.43 (28.73-36.23)	6.50	0.73 (0.57-0.93)	0.01^a
Right	32 (28.4-44)	19.47 (15.23-23.3)	13.25	0.50 (0.34-0.73)	< 0.01^b
Gene
RAS/BRAF wild-type	41.57 (35-57.5)	32.6 (27.87-36.07)	9.22	0.62 (0.45-0.84)	< 0.01^b
RAS/BRAF mutant	32.47 (28.4-40.6)	26.38 (22.53-29.63)	6.97	0.67 (0.50-0.90)	< 0.01^b
Local treatment of liver metastases
Yes	48.43 (35.5-64)	31.25 (28.27-34.43)	13.25	0.54 (0.38-0.75)	< 0.01^b
No	31.9 (28.8-39)	20.28 (17.2-24.37)	13.60	0.59 (0.45-0.79)	< 0.01^b
Treatment lines
Before the third line	32.7 (30-41)	25.8 (23.3-28.93)	9.72	0.69 (0.55-0.87)	< 0.01^b
After the third line	43.73 (35-57.5)	32.6 (29.8-36.7)	11.14	0.48 (0.30-0.74)	< 0.01^b
Only liver metastasis	33.53 (28.4-62.9)	30.7 (27.4-36.23)	6.60	0.65 (0.46-0.90)	0.01^a
Combined with extrahepatic metastasis	36.53 (31.4-43)	25.8 (21.3-29.63)	10.82	0.65 (0.50-0.84)	< 0.01^b

^aP < 0.05.

^bP < 0.01.

RAS: Rat sarcoma viral oncogene homolog; BRAF: B-Raf proto-oncogene, serine/threonine kinase; mOS: Median overall survival; HR: Hazard ratio; CI: Confidence interval.

Full Size Table

Citation: Bian JY, Sun YX, Wang LF, He WT, Liu CB, Wang XQ, Zhang T. Integrated Chinese and Western medicine prolong survival in colorectal cancer with liver metastasis: A retrospective cohort study. World J Clin Oncol 2026; 17(5): 118265
URL: https://www.wjgnet.com/2218-4333/full/v17/i5/118265.htm
DOI: https://dx.doi.org/10.5306/wjco.v17.i5.118265

Bian JY, Sun YX, Wang LF, He WT, Liu CB, Wang XQ, Zhang T. Integrated Chinese and Western medicine prolong survival in colorectal cancer with liver metastasis: A retrospective cohort study. World J Clin Oncol 2026; 17(5): 118265 [DOI: 10.5306/wjco.v17.i5.118265]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.